Cold atmospheric plasma-activated liquid inhibits peritoneal metastasis in drug-resistant ovarian cancer by targeting the epithelial-mesenchymal transition

Jinren Liu & Guanjun Zhang et al. · 2025-08-07

1Citations
Ovarian cancer remains a significant challenge in oncology due to its aggressive nature, late-stage diagnosis, and high rates of chemoresistance, particularly to platinum-based therapies like cisplatin. The epithelial-mesenchymal transition (EMT) is a key driver of ovarian cancer metastasis and drug resistance, highlighting the need for novel therapeutic strategies. Cold atmospheric plasma (CAP) and plasma-activated liquids (PAL), including plasma-activated medium (PAM) and saline (PAS), have emerged as promising anticancer agents, generating reactive oxygen and nitrogen species (RONS) that selectively target cancer cells. This study investigates the potential of PAL to inhibit the invasion and metastasis of cisplatin-resistant ovarian cancer cells and explores its synergistic effects with cisplatin. In vitro, PAM reduced proliferation, migration, and invasion of cisplatin-resistant ovarian cancer cells (A2780/DDP and SKOV3/DDP) while downregulating EMT-related proteins (N-cadherin, β-catenin, vimentin). H
TL;DR

In vivo studies using an orthotopic mouse model confirmed that PAS combined with low-dose cisplatin effectively suppressed tumor growth and metastasis with minimal side effects, underscoring the potential of PAL as an adjuvant therapy for cisplatin-resistant ovarian cancer, offering a novel approach to overcome drug resistance and inhibit metastasis.

AI-generated by Semantic Scholar

Authors
Jinren Liu, Xiangni Wang, Yixin Cui, Jiajia Lu, Zhirou He, Yulin Xu, Rongrong Li, Guimin Xu, Lingge Gao, Xiaolin Fan, Xili Wu, Xingmin Shi, Guanjun Zhang